The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
暂无分享,去创建一个
M. Capecchi | P. Hrelia | R. Danesi | S. Angelini | G. Bocci | S. Galimberti | C. Baratè | M. Petrini | A. Paolo | F. Guerrini | R. Arici | G. Cervetti | G. Fontanelli | E. Ciabatti | S. Grassi | M. Polillo | Giulia Fontanelli | Marialuisa Polillo
[1] H. W. Lee,et al. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Radich,et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy , 2013, Haematologica.
[3] Martin C. Müller,et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. , 2013, Blood.
[4] A. Nagler,et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC , 2012, Hematological oncology.
[5] E. Wiemer,et al. A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients , 2012, Clinical Cancer Research.
[6] D. Marin,et al. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia , 2012, American journal of hematology.
[7] M. Jarošová,et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting , 2012, Annals of Hematology.
[8] D. Colomer,et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. , 2011, Leukemia research.
[9] Andrew C. Hooker,et al. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.
[10] N. Takahashi,et al. Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic‐Phase Chronic Myeloid Leukemia , 2010, Clinical pharmacology and therapeutics.
[11] T. Naoe,et al. Trough plasma concentration of imatinib reflects BCR–ABL kinase inhibitory activity and clinical response in chronic‐phase chronic myeloid leukemia: A report from the BINGO study , 2010, Cancer science.
[12] D. Marin,et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Excoffier,et al. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows , 2010, Molecular ecology resources.
[14] M. Pirmohamed,et al. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters , 2009, Leukemia.
[15] G. Szakács,et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.
[16] Simona Soverini,et al. Response definitions and European Leukemianet Management recommendations. , 2009, Best practice & research. Clinical haematology.
[17] R. Savic,et al. Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.
[18] K. Siminovitch,et al. Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia , 2009, Clinical Cancer Research.
[19] B. Geoerger,et al. Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults , 2008, Clinical Cancer Research.
[20] M. Baccarani,et al. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Nicholas Moore,et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2007, Blood.
[22] H. Koepsell,et al. Regulation of the human organic cation transporter hOCT1 , 2004, Journal of cellular physiology.
[23] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[24] E. Niclas Jonsson,et al. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..
[25] A. Schinkel,et al. Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.
[26] Stuart L. Beal,et al. Commentary on Significance Levels for Covariate Effects in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[27] H. Koepsell,et al. Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.
[28] H. Koepsell,et al. Drug excretion mediated by a new prototype of polyspecific transporter , 1994, Nature.
[29] T. Buclin,et al. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. , 2011, The Lancet. Oncology.
[30] A. Zannettino,et al. Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity , 2010, Leukemia.
[31] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.